June 12, 2017 06:58 AM EDT

With an FDA decision looming, Flexion touts new data spotlighting a safety edge for osteoarthritis drug

Now that Flexion $FLXN is less than four months away from an FDA decision on its new osteoarthritis drug Zilretta (FX006), the biotech has floated …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With an FDA de­ci­sion loom­ing, Flex­ion touts new da­ta spot­light­ing a safe­ty edge for os­teoarthri­tis drug